Article
[Research progress of hepatitis C in 2018].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 20 Jan 2019
Wei L
Abstract excerpt
Up to now, all major direct-acting antiviral agents (DAAs) have been approved, pan-genotypic regimens are recommended globally, simple monitoring strategy is recommended. In 2018, hepatitis C research focused more on accessibility, rather than new regimens. With the joint efforts of government and social groups, more infected people are getting affordable treatment. In addition approval of DAAs from global...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
